Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Amortization of Deferred Charges (2016 - 2023)

Fate Therapeutics (FATE) has disclosed Amortization of Deferred Charges for 12 consecutive years, with $7.2 million as the latest value for Q1 2023.

  • For the quarter ending Q1 2023, Amortization of Deferred Charges rose 557.77% year-over-year to $7.2 million, compared with a TTM value of $7.2 million through Dec 2023, up 168.91%, and an annual FY2023 reading of $7.2 million, up 168.91% over the prior year.
  • Amortization of Deferred Charges was $7.2 million for Q1 2023 at Fate Therapeutics, up from $1.1 million in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $7.2 million in Q1 2023 and bottomed at -$331000.0 in Q2 2022.
  • Average Amortization of Deferred Charges over 5 years is $1.0 million, with a median of $623000.0 recorded in 2021.
  • The sharpest move saw Amortization of Deferred Charges tumbled 747.37% in 2019, then skyrocketed 2700.0% in 2020.
  • Year by year, Amortization of Deferred Charges stood at -$123000.0 in 2019, then surged by 1604.07% to $1.8 million in 2020, then crashed by 30.43% to $1.3 million in 2021, then decreased by 12.2% to $1.1 million in 2022, then skyrocketed by 536.81% to $7.2 million in 2023.
  • Business Quant data shows Amortization of Deferred Charges for FATE at $7.2 million in Q1 2023, $1.1 million in Q4 2022, and $783000.0 in Q3 2022.